CPI Logo-Color.png
Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead Programs
January 03, 2019 07:00 ET | Constellation Pharmaceuticals , Inc.
Constellation CEO Jigar Raythatha will present at the J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019, at 4PM PST/7PM ESTThe presentation will include updated results from the first...
CPI Logo-Color.png
Constellation Pharmaceuticals Receives FDA Fast Track Designation for CPI-0610 in Treatment of Myelofibrosis
November 01, 2018 07:00 ET | Constellation Pharmaceuticals , Inc.
- Recently Expanded and Enhanced MANIFEST Phase 2 Trial Ongoing with Proof of Concept Data Expected Mid-2019 CAMBRIDGE, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals,...
CPI Logo-Color.png
Constellation Pharmaceuticals Enhances and Expands Phase 2 MANIFEST Study of CPI-0610 in Myelofibrosis
October 10, 2018 16:30 ET | Constellation Pharmaceuticals , Inc.
– Amends second-line trial design to stratify for transfusion dependence based on positive preliminary data – – Expands study to include an additional arm evaluating CPI-0610 as first-line therapy in...